68c40803-064b-47ef-9e73-9d07e6f183d9_98dc2753
Pfizer’s Covid-19 pill is one step closer to clinical use in China, with state-owned China Meheco Corp securing a deal with Pfizer to commercialise the drug within the year.
The Chinese company had signed a contract with Pfizer and was authorised to supply Paxlovid in China during the 2022 agreement period, China Meheco said in a statement on Wednesday night.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
